Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 40: 279-287, 1994;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Potter, W. Z.
Right arrow Articles by Manji, H. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Potter, W. Z.
Right arrow Articles by Manji, H. K.

Clinical Chemistry, Vol 40, 279-287, Copyright © 1994 by American Association for Clinical Chemistry

Catecholamines in depression: an update

WZ Potter and HK Manji
Section on Clinical Pharmacology, National Institute of Mental Health, Bethesda, MD 20892.

Despite extensive research, the biochemical abnormalities underlying the predisposition to and the pathogenesis of affective disorders remain to be clearly established. Efforts to study norepinephrine (NE) output and function have utilized biochemical assays, neuroendocrine challenge strategies, and measures of peripheral blood cell receptors; the cumulative database points to a dysregulation of the noradrenergic system. Depressed patients (in particular, melancholic, unipolar subjects) excrete disproportionately greater amounts of NE and its major extraneuronal metabolite, normetanephrine, than do controls. Depressed patients also show subsensitive neuroendocrine (growth hormone) and biochemical (inhibition of adenylate cyclase) responses to alpha 2-adrenergic agonists, suggesting that subsensitivity of nerve terminal alpha 2 autoreceptors may underlie the exaggerated plasma NE observed in response to various challenges in affective disorders. Future advances in brain imaging techniques and in the molecular biology of adrenergic receptor-coupled signal transduction systems offer promise for meaningful advances in our understanding of the pathophysiology of affective disorders.


The following articles in journals at HighWire Press have cited this article:


Home page
 Psychosom. Med.Home page
M. A.L. Van Tilburg, C. C. McCaskill, J. D. Lane, C. L. Edwards, A. Bethel, M. N. Feinglos, and R. S. Surwit
Depressed Mood Is a Factor in Glycemic Control in Type 1 Diabetes
Psychosom Med, July 1, 2001; 63(4): 551 - 555.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M.-L. Wong, M. A. Kling, P. J. Munson, S. Listwak, J. Licinio, P. Prolo, B. Karp, I. E. McCutcheon, T. D. Geracioti Jr., M. D. DeBellis, et al.
Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: Relation to hypercortisolism and corticotropin-releasing hormone
PNAS, January 4, 2000; 97(1): 325 - 330.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
J. H. Markovitz, L. Tolbert, and S. E. Winders
Increased Serotonin Receptor Density and Platelet GPIIb/IIIa Activation Among Smokers
Arterioscler Thromb Vasc Biol, March 1, 1999; 19(3): 762 - 766.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
J. A. Garcia-Sevilla, P. V. Escriba, M. Sastre, C. Walzer, X. Busquets, G. Jaquet, D. J. Reis, and J. Guimon
Immunodetection and Quantitation of Imidazoline Receptor Proteins in Platelets of Patients With Major Depression and in Brains of Suicide Victims
Arch Gen Psychiatry, September 1, 1996; 53(9): 803 - 810.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the American Association for Clinical Chemistry.